▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #934 by analyst upside · 2026-06-27
SVRA
Savara Inc.
Healthcare · Market Cap $1B · P/E 0x
ANALYST PRICE TARGET
+85.4%
implied upside to consensus target
Current Price $5.9
Consensus Target $10.94
Bull Target $16.0
Bear Target $9.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
6
Hold
0
Sell
0
52-Week Low $1.98
52-Week High $7.0
YTD Return +4.6%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) N/A
Forward P/E -20.1x
EPS (TTM) $-0.55
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.98
52-Week High $7.0
Current Price $5.9
Bear Target $9.0
Bull Target $16.0
● Now $5.9 ● Target $10.94
TRADING DATA
Avg Volume 1.5M
YTD Return +4.6%
Analyst Count 8
Consensus Buy
Upside to Target +85.4%
Last Updated 2026-06-27

ANALYST SUMMARY

Savara Inc. (SVRA) is currently trading at $5.9 with a Wall Street consensus price target of $10.94, implying potential upside of 85.4% over the next 12 months. 8 analysts currently cover SVRA, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $16.0, while the most cautious has a target of $9.0.

SVRA operates in the Healthcare sector with a market capitalisation of $1B. The stock is up 4.6% year-to-date and is currently trading near the upper end of its 52-week range of $1.98 – $7.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

GTBIF +112.0%
Green Thumb Industries Inc.
$2B · P/E 14.2x · Buy
COLL +48.5%
Collegium Pharmaceutical, Inc.
$1B · P/E 17.8x · Buy
PAHC +43.9%
Phibro Animal Health Corporation
$1B · P/E 13.7x · Hold
ZVRA +106.3%
Zevra Therapeutics, Inc.
$799M · P/E 6.6x · Buy
NUTX +41.5%
Nutex Health Inc.
$1B · P/E 12.2x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for SVRA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. — Reiterated
Buy → Buy 2025-12-23 31% win rate (48 calls)
Wells Fargo — Reiterated
Overweight → Overweight 2025-12-18 Building track record
Oppenheimer — Reiterated
Outperform → Outperform 2025-11-14 14% win rate (7 calls)
Citizens — Reiterated
Market Outperform → Market Outperform 2025-11-13 Building track record
JMP Securities — Reiterated
Market Outperform → Market Outperform 2025-10-23 Building track record
Guggenheim — Reiterated
Buy → Buy 2025-09-09 62% win rate (8 calls)
Oppenheimer — Reiterated
Outperform → Outperform 2025-09-08 14% win rate (7 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2025-09-03 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
50
out of 100
Coverage depth
17/30
Consensus clarity
6/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →